OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 501 - 510 of 797 studies

The PACS Study: Understanding paediatric ambulatory chemotherapy service provision within the UK

Respiratory

A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Assess the Efficacy, Safety, and Tolerability of AGMB-447 in Participants with Idiopathic Pulmonary Fibrosis (INSPIRIA)

STRIDE - (Step Tracking and Remote In-home Disease Evaluation): A Prospective Feasibility Study of Wearable-Based Digital Monitoring in Patients with Malignant Pleural Effusion Undergoing Pleural Intervention

Neurological

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Ro7568282 In Participants With Early-Stage Parkinson’s Disease (TARBELA-PD)

Cancer and neoplasms

Randomized Phase 2/3 Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

Respiratory

A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults With Idiopathic Pulmonary Fibrosis (SURPASS-IPF)

Cancer and neoplasms

A Phase 1/2, Open-Label, First-In-Human Trial Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Antitumour Activity Of Odm-216 In Participants With Advanced Solid Tumours (BICIDES)

Respiratory

A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)

Does early surgery for unilateral congenital cataract affect incidence of nystagmus and incidence and type of strabismus?

Cancer and neoplasms

A Phase 1/2, Open-label Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 in Combination with Pembrolizumab in Patients with Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Squamous Cell Carcinoma (VB-C-03)